Search
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … [A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalin MS therapy. … [A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard
Clonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigationalClonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD. … [L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Categories: Sympathomimetics in Glaucoma TherapySynonyms: 2,6-Dichloro-N-2-imidazolidinylidenebenzenamineCinnamaldehyde
go.drugbank.com/drugs/DB14184ApprovedIt occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test. … Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour.
Categories: Compounds used in a research, industrial, or household settingSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. … [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]
Eucalyptus oil
go.drugbank.com/drugs/DB11114ApprovedIt is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. … It is also shown to exhibit antibacterial activity against some bacterial species and cough suppressant actions.
Mixtures: Cellzyme ON-TOX, Cellzyme ON-TOXNazartinib
go.drugbank.com/drugs/DB16250InvestigationalNazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Categories: Topoisomerase II InhibitorsCalfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalIt is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. … Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency.
Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-